PLUS

HEADLINES TREATMENT REGIMENS FROM THE ADVISORY BOARD PUBLISHERS ALLIANCE TOOLS MULTIMEDIA CME

Sirolimus Lowers NMSC Risk in Transplant Recipients

Share this article:

Switching from a calcineurin inhibitor (CNI) to sirolimus for immunosuppression may decrease the risk of nonmelanoma skin cancer (NMSC) in kidney transplant recipients with a history of NMSC, according to researchers.

In a prospective, multi-center study, Scott B. Campbell, MD, Consultant Renal Physician at Princess Alexandra Hospital, and collaborators randomly assigned 86 kidney transplant recipients (at least one year post-transplant) with a history of NMSC to continue receiving CNI therapy or convert to sirolimus. The authors noted that sirolimus is known to have antineoplastic effects.

The mean length of follow-up for the intent-to-treat population (that is, on- and off-therapy periods) was 1.68 and 1.74 years for the sirolimus and CNI groups, respectively. The annual NMSC rate was significantly lower with sirolimus than with CNI (1.31 vs. 2.48 lesions/patient-year). Squamous cell carcinoma also occurred at a lower rate in the sirolimus group. The rate of basal cell carcinoma was similar for both groups. A significantly lower proportion of sirolimus recipients experienced new or recurrent NMSC (56.4% vs. 80.9%), Dr. Campbell's group reported in the American Journal of Transplantation.

Acute rejection occurred in none of the sirolimus patients and in one of the CNI patients. The two groups had a similar incidence of treatment-emergent adverse events, but discontinuation rates were significantly higher in the sirolimus group (46.2% vs. 0%).

The authors noted that kidney transplant recipients have greater rates of de novo and recurrent neoplasms compared with the age-matched general population. Most of these cancers involve the skin. NMSC accounts for more than 90% of post-transplant skin cancers, the investigators noted. They cited previous research showing that among kidney transplant recipients, about 75% of those who had at least one skin cancer prior to transplantation will develop an average of 16-20 NMSC lesions post-transplant, with a median of six months to onset.

“The results of this and other studies examining the reduction of skin and nonskin malignancies suggest a benefit in converting to a sirolimus-based immunosuppressive regimen,” the researchers concluded.

Share this article:
You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs